(Q57076791)

ORCID Public Data File 2021

publication date

October 2008

0 references

published in

Future rheumatology

0 references

volume

3

0 references

issue

5

0 references

page(s)

421-427

0 references

cites work

New insights into gout epidemiology

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Milestones in the treatment of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Serum urate levels and gout flares: analysis from managed care data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Efficacy and safety of desensitization to allopurinol following cutaneous reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Long-term remission from gout associated with fenofibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Relation between adverse events associated with allopurinol and renal function in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Assessment of outcome in clinical trials of gout - a review of current measures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421

Uric acid and oxidative stress: relative impact on cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460816.3.5.421